Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F vs BRAVELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Induction of ovulation in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian stimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Induction of spermatogenesis in men with hypogonadotropic hypogonadism
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
Terminal elimination half-life is approximately 24 hours (range 16–32 hours) following subcutaneous administration. This supports once-daily dosing.
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
Metabolized via hepatic and renal pathways; exact enzymes not fully characterized. Clearance involves proteolytic degradation and renal excretion.
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Primarily renal (hepatic metabolism and biliary excretion are minor routes). Approximately 80% of the dose is excreted in urine, with less than 20% in feces.
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Approximately 70–80% bound to plasma proteins, primarily albumin.
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
Approximately 0.3–0.6 L/kg, indicating distribution primarily into extracellular fluid.
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
Subcutaneous: approximately 70% (range 60–80%) relative to intravenous administration.
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min).
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
No specific Child-Pugh based modifications; caution in severe hepatic impairment.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Not indicated for use in children; no established pediatric dosing.
Not indicated for use in pediatric patients; safety and efficacy not established.
Not indicated for use in elderly patients; no specific dosing recommendations.
Not indicated for use in geriatric patients; safety and efficacy not established.
GONAL-F should only be used by physicians experienced in fertility treatment. Ovarian hyperstimulation syndrome (OHSS) is a serious, potentially fatal complication. Patients should be monitored for signs of OHSS. GONAL-F may increase the risk of multiple gestation and pregnancy loss.
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
Ovarian hyperstimulation syndrome (OHSS): can progress to severe form with respiratory distress, oliguria, and thromboembolism,Ovarian torsion,Multiple pregnancy,Ectopic pregnancy,Pulmonary embolism,Ovarian neoplasia (rare),Hypersensitivity reactions including anaphylaxis
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
Hypersensitivity to follitropin alfa or any excipient,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine, pituitary),Pregnancy and lactation,Ovarian cyst or enlargement of unknown origin
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
No specific food interactions. Maintain adequate hydration to reduce OHSS risk.
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
GONAL-F (follitropin alfa) is not indicated for use during pregnancy and has no direct fetal risk as it is administered for ovulation induction prior to conception. However, if inadvertent administration occurs during pregnancy, there is a potential risk of luteal phase defect and multiple gestation. Human data on fetal effects are limited; animal studies show no evidence of teratogenicity at clinically relevant doses. No consistent pattern of malformations has been reported.
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
It is not known whether follitropin alfa is excreted in human breast milk. Due to its protein nature and high molecular weight (approximately 30 k Da), transfer into milk is likely limited. However, because GONAL-F is typically used in fertility treatments and not during breastfeeding, no specific M/P ratio is available. Caution is advised if use is considered during lactation.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
GONAL-F is contraindicated during pregnancy; therefore, no dosing adjustments during pregnancy are applicable. Treatment should be discontinued if pregnancy is confirmed.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
GONAL-F (follitropin alfa) is a recombinant FSH used for ovulation induction and controlled ovarian stimulation. Monitor estradiol levels and follicle growth via ultrasound to adjust dosing and reduce OHSS risk. Use the lowest effective dose. Do not administer if ovarian cyst or enlargement is present. LH supplementation may be needed in hypogonadotropic hypogonadism.
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
Inject subcutaneously as directed; rotate injection sites to avoid lipodystrophy.,Report severe pelvic pain, nausea, weight gain, or shortness of breath immediately (OHSS symptoms).,Missed doses can affect cycle; do not double dose without consulting healthcare provider.,Store vials in refrigerator (2-8°C) before mixing; after mixing, use immediately or store refrigerated for up to 28 days.,Avoid pregnancy tests until instructed; false positives may occur from h CG trigger.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F vs BRAVELLE, answered by our medical review team.
GONAL-F is a Gonadotropin that works by GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.. BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F and BRAVELLE depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F is: Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.. The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F and BRAVELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F is classified as Category C. GONAL-F (follitropin alfa) is not indicated for use during pregnancy and has no direct fetal risk as it is administered for ovulation induction prior to conception. However, if ina. BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.